Physician profile
David Ellis
NPI 1891792214
$18,213.31
in general payments reported to CMS, 2019-2025
46 companies · $4,427 in 2025
The $4,427 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,585 · 2020: $1,655 · 2021: $2,083 · 2022: $2,457 · 2023: $3,053 · 2024: $2,954 · 2025: $4,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $16.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,416.82 |
| Education | $16.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,439.26 | 2019-2025 | |
| Janssen Biotech, INC. | $2,246.06 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,553.19 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,225.28 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $992.05 | 2019-2025 | |
| Qol Medical, LLC | $919.49 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $654.83 | 2021-2024 | Zeposia |
| Genzyme Corporation | $584.81 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $488.58 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $456.07 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $403.67 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $355.49 | 2022-2023 | Zeposia |
| Redhill Biopharma INC. | $353.12 | 2020-2024 | Aemcolo, Talicia |
| Aimmune Therapeutics, INC. | $352.03 | 2024-2025 | Zenpep, Vowst |
| Braintree Laboratories, INC. | $343.29 | 2019-2024 | Sutab, Suflave |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $332.58 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $270.21 | 2019-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $223.73 | 2019-2025 | Rebyota |
| Lilly USA, LLC | $186.63 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $158.84 | 2022-2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $145.58 | 2020-2023 | |
| Endo Pharmaceuticals INC. | $143.79 | 2019-2020 | |
| Madrigal Pharmaceuticals | $143.29 | 2025 | Rezdiffra |
| Alnylam Pharmaceuticals INC. | $141.02 | 2023 | Givlaari |
| Merck Sharp & Dohme LLC | $137.08 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $100.53 | 2020-2021 | |
| Allergan, INC. | $88.23 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $83.86 | 2023-2024 | Kristalose |
| Ipsen Biopharmaceuticals, INC | $82.48 | 2024-2025 | Iqirvo |
| Ucb, INC. | $80.87 | 2019 | |
| Fresenius Kabi USA, LLC | $74.07 | 2023 | Idacio |
| Exact Sciences Corporation | $63.16 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $56.87 | 2019 | |
| Celltrion USA INC. | $44.94 | 2024 | Vegzelma, Zymfentra |
| Sandoz INC. | $42.80 | 2023-2024 | Hyrimoz |
| Alfasigma USA, INC. | $39.66 | 2020 | |
| Amgen INC. | $37.19 | 2022-2023 | Amjevita |
| Novo Nordisk INC | $22.52 | 2025 | Wegovy |
| Medtronic, INC. | $21.70 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.82 | 2024 | Cyltezo |
| Evoke Pharma, INC. | $19.83 | 2021 | |
| Vivus LLC | $19.52 | 2025 | Qsymia |
| Teva Pharmaceuticals USA, INC. | $17.48 | 2024 | Simlandi |
| W. L. Gore & Associates, INC. | $17.43 | 2021 | |
| Mimedx Group, INC. | $16.41 | 2025 | |
| Digestive Care, INC. | $12.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.